Solid Biosciences (SLDB) EBT (2017 - 2024)
Solid Biosciences (SLDB) has disclosed EBT for 8 consecutive years, with -$38.0 million as the latest value for Q4 2024.
- Quarterly EBT fell 84.64% to -$38.0 million in Q4 2024 from the year-ago period, while the trailing twelve-month figure was -$120.6 million through Dec 2024, down 24.19% year-over-year, with the annual reading at -$169.1 million for FY2025, 40.22% down from the prior year.
- EBT hit -$38.0 million in Q4 2024 for Solid Biosciences, down from -$32.9 million in the prior quarter.
- In the past five years, EBT ranged from a high of -$16.9 million in Q1 2021 to a low of -$38.0 million in Q4 2024.
- Historically, EBT has averaged -$24.1 million across 5 years, with a median of -$22.8 million in 2020.
- Biggest five-year swings in EBT: surged 37.62% in 2023 and later crashed 84.64% in 2024.
- Year by year, EBT stood at -$21.4 million in 2020, then grew by 12.69% to -$18.7 million in 2021, then tumbled by 77.1% to -$33.0 million in 2022, then soared by 37.62% to -$20.6 million in 2023, then plummeted by 84.64% to -$38.0 million in 2024.
- Business Quant data shows EBT for SLDB at -$38.0 million in Q4 2024, -$32.9 million in Q3 2024, and -$25.3 million in Q2 2024.